- MEI Pharma Inc (NASDAQ:MEIP) priced the underwritten public offering of 17.5 million shares at $2.60/share for gross proceeds of $45.5 million.
- The offer price represents a discount of almost 14% from the last close price of $3.03 on Wednesday. The offering will close by December 29.
- Jefferies, Stifel, and Wells Fargo Securities are acting as joint book-running managers.
- LifeSci Capital and H.C. Wainwright & Co. are acting as co-managers.
- The Company will use the proceeds of the offering and other available funds to progress its clinical development programs and prepare for and support the commercial launch of zandelisib.
- Related Link: MEI Pharma, Kyowa Kirin Reveal Data From Zandelisib Trial In Follicular Lymphoma.
- Price Action: MEIP shares are down 13.4% at $2.62 during the market session on the last check Thursday.
Duluth Holdings Q1 EPS $(0.04) Beats $(0.18) Estimate, Sales $122.90M Beat $116.10M Estimate
Duluth Holdings (NASDAQ:DLTH) reported quarterly losses of $(0.04) per share which beat the analyst consensus estimate of $(0.18) by 77.78 percent. This is a 300 percent decrease over earnings of $0.02 per share from the
